NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Oruka Therapeutics, Inc. ORKA
18 fiscal years on record · USD · FY2025 reported · SEC filings only
$-105.4M
$-88.4M
Growth
—
Revenue, FY2025 · full 18-year series below
Revenue $M
Net income $M
FY2023 · Revenue 0.0 · Net income -5.3
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
—
ROE
FY2025 · ROE -22.3%
Each USD of equity lost 22 cents this year.
The 18-year record
18 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | · | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | · | · | · | · | · | · |
| Operating income $B | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | · | · | · |
| EBITDA $B | −0.1 | · | · | · | · | · | · | · | · | · | · | −0.0 | −0.0 | −0.0 | · | · | · | · |
| Income tax $B | · | 0.0 | 0.0 | 0.0 | −0.0 | −0.0 | −0.0 | −0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | · | · | · | · | · |
| Net income $B | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | · | −0.0 | −0.0 | · | · | · |
| EPS, diluted $ | · | −0.37 | −0.69 | −1.39 | −2.07 | −4.15 | −10.31 | −1.77 | −1.81 | −1.82 | −3.31 | −1.04 | −1.94 | −3.21 | −0.99 | · | · | · |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | −22.3 | −13.6 | −21.4 | −39.6 | −36.0 | −80.4 | −97.3 | −113.9 | −54.6 | −43.3 | −63.9 | −75.1 | −100.0 | −85.8 | −118.7 | · | · | · |
| Shares out B | 0.05 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.00 | 0.02 | 0.00 | 0.00 | 0.01 | · | · | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 61 reconciliationsAUDITED
Reconciled in 18 of 19 fiscal years. 15 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2007